FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2987487791> ?p ?o ?g. }

• W2987487791 abstract "Abstract Purpose Many rare ovarian cancer subtypes such as small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) have poor prognosis due to their aggressive nature and resistance to standard platinum and taxane based chemotherapy. The development of effective therapeutics has been hindered by the rarity of such tumors. We sought to identify targetable vulnerabilities in rare ovarian cancer subtypes. Experimental Design We compared the global proteomic landscape of six cases each of endometrioid ovarian cancer (ENOC), clear cell ovarian cancer (CCOC), and SCCOHT to the most common subtype high grade serous ovarian cancer (HGSC) to identify potential therapeutic targets. Immunohistochemistry of tissue microarrays were used as validation of ASS1 deficiency. The efficacy of arginine-depriving therapeutic ADI-PEG20 was assessed in vitro using cell lines and patient derived xenograft mouse models representing SCCOHT. Results Global proteomic analysis identified low ASS1 expression in ENOC, CCOC, and SCCOHT compared to HGSC. Low ASS1 levels were validated through IHC in a large patient cohort. The lowest levels of ASS1 were observed in SCCOHT, where ASS1 was absent in 2/15 cases, and expressed in less than 5% of the tumor cells in 8/15 cases. ASS1 deficient ovarian cancer cells were sensitive to ADI-PEG20 treatment regardless of subtype in vitro . Furthermore, in two cell line mouse xenograft models and one patient derived mouse xenograft model of SCCOHT, once a week treatment of ADI-PEG20 (30mg/kg and 15mg/kg) inhibited tumor growth in vivo . Conclusions Preclinical in vitro and in vivo studies identified ADI-PEG20 as a potential therapy for patients with rare ovarian cancers including SCCOHT. Translational relevance Many rare ovarian cancers lack effective management strategies and are resistant to the standard platinum- and taxane-based chemotherapy. Thus, for a rare ovarian cancer subtype like small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) - an aggressive malignancy affecting young women in their twenties, effective targeted therapeutics are urgently needed. We used global proteomics to identify a deficiency in arginosuccinate synthase (ASS1) as a common feature among some rare ovarian cancer subtypes. Using in-vitro and in-vivo models, we demonstrated that the arginine-depriving investigational agent ADI-PEG20 effectively inhibited cell growth in ASS1 deficient ovarian cancers including SCCOHT, establishing it as a potential therapeutic agent for rare ovarian cancer subtypes deficient in ASS1. Further clinical investigation is warranted." @default.
• W2987487791 created "2019-11-22" @default.
• W2987487791 creator A5000473665 @default.
• W2987487791 creator A5001261720 @default.
• W2987487791 creator A5004059894 @default.
• W2987487791 creator A5007696945 @default.
• W2987487791 creator A5008727204 @default.
• W2987487791 creator A5010665800 @default.
• W2987487791 creator A5019258605 @default.
• W2987487791 creator A5019550268 @default.
• W2987487791 creator A5028219690 @default.
• W2987487791 creator A5034194104 @default.
• W2987487791 creator A5039549626 @default.
• W2987487791 creator A5040540518 @default.
• W2987487791 creator A5040659461 @default.
• W2987487791 creator A5044916326 @default.
• W2987487791 creator A5046538735 @default.
• W2987487791 creator A5047823441 @default.
• W2987487791 creator A5051551574 @default.
• W2987487791 creator A5052006916 @default.
• W2987487791 creator A5058376745 @default.
• W2987487791 creator A5062049233 @default.
• W2987487791 creator A5064691269 @default.
• W2987487791 creator A5079679478 @default.
• W2987487791 creator A5083390751 @default.
• W2987487791 creator A5088071204 @default.
• W2987487791 date "2019-11-17" @default.
• W2987487791 modified "2023-09-26" @default.
• W2987487791 title "Arginine depletion through ADI-PEG20 to treat argininosuccinate synthase deficient ovarian cancer, including small cell carcinoma of the ovary, hypercalcemic type" @default.
• W2987487791 cites W1488106034 @default.
• W2987487791 cites W1941960325 @default.
• W2987487791 cites W1966242225 @default.
• W2987487791 cites W1972182149 @default.
• W2987487791 cites W1979879868 @default.
• W2987487791 cites W1987674332 @default.
• W2987487791 cites W1993925306 @default.
• W2987487791 cites W2002885198 @default.
• W2987487791 cites W2013321862 @default.
• W2987487791 cites W2014816727 @default.
• W2987487791 cites W2034852369 @default.
• W2987487791 cites W2036407487 @default.
• W2987487791 cites W2064695540 @default.
• W2987487791 cites W2070436739 @default.
• W2987487791 cites W2080915191 @default.
• W2987487791 cites W2081837283 @default.
• W2987487791 cites W2113798012 @default.
• W2987487791 cites W2119097025 @default.
• W2987487791 cites W2125836866 @default.
• W2987487791 cites W2156883040 @default.
• W2987487791 cites W2199159118 @default.
• W2987487791 cites W2320990756 @default.
• W2987487791 cites W2512678052 @default.
• W2987487791 cites W2517861366 @default.
• W2987487791 cites W2529501230 @default.
• W2987487791 cites W2555058267 @default.
• W2987487791 cites W2570729870 @default.
• W2987487791 cites W2607808741 @default.
• W2987487791 cites W2608835133 @default.
• W2987487791 cites W2737389832 @default.
• W2987487791 cites W2749938176 @default.
• W2987487791 cites W2807649309 @default.
• W2987487791 cites W2811301013 @default.
• W2987487791 cites W2890293509 @default.
• W2987487791 cites W2890419621 @default.
• W2987487791 cites W2891585088 @default.
• W2987487791 cites W2892293198 @default.
• W2987487791 cites W2896753349 @default.
• W2987487791 cites W2915022564 @default.
• W2987487791 cites W2953124185 @default.
• W2987487791 cites W2953307540 @default.
• W2987487791 doi "https://doi.org/10.1101/845586" @default.
• W2987487791 hasPublicationYear "2019" @default.
• W2987487791 type Work @default.
• W2987487791 sameAs 2987487791 @default.
• W2987487791 citedByCount "0" @default.
• W2987487791 crossrefType "posted-content" @default.
• W2987487791 hasAuthorship W2987487791A5000473665 @default.
• W2987487791 hasAuthorship W2987487791A5001261720 @default.
• W2987487791 hasAuthorship W2987487791A5004059894 @default.
• W2987487791 hasAuthorship W2987487791A5007696945 @default.
• W2987487791 hasAuthorship W2987487791A5008727204 @default.
• W2987487791 hasAuthorship W2987487791A5010665800 @default.
• W2987487791 hasAuthorship W2987487791A5019258605 @default.
• W2987487791 hasAuthorship W2987487791A5019550268 @default.
• W2987487791 hasAuthorship W2987487791A5028219690 @default.
• W2987487791 hasAuthorship W2987487791A5034194104 @default.
• W2987487791 hasAuthorship W2987487791A5039549626 @default.
• W2987487791 hasAuthorship W2987487791A5040540518 @default.
• W2987487791 hasAuthorship W2987487791A5040659461 @default.
• W2987487791 hasAuthorship W2987487791A5044916326 @default.
• W2987487791 hasAuthorship W2987487791A5046538735 @default.
• W2987487791 hasAuthorship W2987487791A5047823441 @default.
• W2987487791 hasAuthorship W2987487791A5051551574 @default.
• W2987487791 hasAuthorship W2987487791A5052006916 @default.
• W2987487791 hasAuthorship W2987487791A5058376745 @default.
• W2987487791 hasAuthorship W2987487791A5062049233 @default.
• W2987487791 hasAuthorship W2987487791A5064691269 @default.
• W2987487791 hasAuthorship W2987487791A5079679478 @default.
• W2987487791 hasAuthorship W2987487791A5083390751 @default.
• W2987487791 hasAuthorship W2987487791A5088071204 @default.

• next